MG
RGLS

Michael Gelband’s Regulus Therapeutics RGLS Stock Holding History

Michael Gelband’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-329,639
Closed -$588K – 2020
2024
Q2 		$588K Buy
+329,639
New +$765K ﹤0.01% 1180

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Michael Gelband's RGLS Position: Q3 2024 in Review

Michael Gelband sold out of Regulus Therapeutics (RGLS) in Q3 2024, closing a stake of 329,639 shares — an estimated $588K sold.

Michael Gelband first reported a position in RGLS in Q2 2024 and held it in 1 quarter. The position peaked at $588K in Q2 2024. 70 funds tracked by Wall St. Rank hold RGLS as of Q3 2024.

  • Michael Gelband reported no remaining Regulus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Michael Gelband sold 329,639 Regulus Therapeutics shares in Q3 2024, an estimated $588K.
  • Michael Gelband first reported a position in Regulus Therapeutics in Q2 2024 and held it in 1 quarter.
  • Michael Gelband's Regulus Therapeutics position peaked at $588K in Q2 2024.
  • 70 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2024.

Based on ExodusPoint Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.